Mammalian target of Rapamycin kinase (mTOR) pathway is often up regulated in cancer and thus intensively pursued as a target to design novel anti-cancer therapies. Approved and emerging drugs targeting mTOR pathway have positively impacted the clinical landscape.
The PI3K/AKT/mTOR pathway is a foremost signaling pathway regulating various hallmarks of cancer that include sustained proliferative signaling, evading growth suppressors, resistance to programmed cell death, consequently enabling replicative immortality, inducing angiogenesis and activating invasion and metastasis (1) . The significance of this pathway stems from the abundant evidence that it is frequently deregulated by various genetic and epigenetic mechanisms in a wide range of tumor types. Aberrant PI3K activation due to activating point mutations or amplification of the PIK3CA gene, genetic loss or loss of function mutations within tumor suppressor PTEN (2) has been associated with increased activity of downstream kinases AKT and mTOR that regulate a myriad of cellular processes (3) . Extensive evidence is now available validating diverse components of this pathway as molecular targets in cancer (4) .
A highly conserved and ubiquitously expressed serine/threonine (Ser/Thr) kinase which is a member of the PI3K related super kinase (PIKK) family, the mammalian target of rapamycin (mTOR), is a fundamental regulator of cell proliferation, differentiation, growth and survival. mTOR is a central node that functions as a sensor of the nutrients, energy, insulin, growth factors, and environmental cues and also acts as a negative regulator of autophagy (5) . These mitogenic signals are transmitted to mTOR via PI3K and AKT which in turn relays it to downstream targets to effectuate the cellular and metabolic responses (6, 7) . Two physically and functionally distinct signaling multi protein complexes are formed by mTOR; mTORC1 (containing Raptor and PRAS40) and mTORC2 (containing Rictor and Protor) (8) . mTORC1, which is the molecular target of rapamycin, regulates protein translation by phosphorylating downstream proteins p70S6K (S6K) and 4E-BP1 (9) , whereas mTORC2 increases the enzymatic activity of AKT by 10-fold by phosphorylating it on Ser473 (10) . As mTOR pathway has emerged as an essential hub in regulating various cellular processes, its activity is tightly regulated in normal physiology. Phosphorylation of S6K by mTOR induces the degradation of IRS1, which in turn decreases insulin-driven AKT activity and, consequently, mTOR activity (11, 12) . AKT destabilizes the TSC1/TSC2 complex and increases mTOR activity. Inhibition of mTORC1 results in the release of the negative feedback loop between S6K and IRS1, leading to hyper activation of AKT (13, 14) . Absence of AKT inhibition due to lack of mTORC2 activity is reported to limit the use of rapamycin and rapa-analogues in several cancers (15) . Moreover, inhibition of both TORC1 and TORC2 negates a recognized feedback mechanism of resistance to current rapalogs (16) . Therefore, a potential for a complete signaling blockade would be achieved by inhibition of both mTORC1 and mTORC2. An increasing panorama of targeted agents inhibiting PI3K/AKT/mTOR pathway are already in clinical trials (17) . Only a couple of mTORC1 inhibitors Everolimus and Temsirolimus have been commercialized. Therefore, there is still a need for effective agents with the potential to maximize clinical benefit, minimize toxicities and aimed at targets complementary to the ones currently available. As a result of these issues, it will be beneficial to have a compound with activity against both mTORC1 and mTORC2. Since angiogenesis plays an important role in tumor growth, having antiangiogenesis activity will be advantageous. Recent reports have emphasized the role of Activin receptor like kinase-1 (ALK1) in regulating cell type-specific transcriptional modulators which collaborate to activate or repress transcription of specific target genes in the angiogenic response (18) . ALK1 is an endothelial cell-restricted receptor of the large TGF-β receptor family, is found to be widely present on tumor blood vessels, most notably in lymphomas and numerous solid cancers (19, 20) . 5 Herein, we describe, P7170, a small molecule inhibitor of mTORC1/mTORC2/ALK1. Preclinical pharmacology illustrates P7170, an orally bioavailable, potent inhibitor of mTORC1 and mTORC2 with its distinctive activity against TGF-β superfamily kinase ALK1. P7170 demonstrates profound growth inhibitory activity in vitro and significant anti-tumor activity in multiple human xenograft models. Its compelling anti-angiogenic activity, both in vitro and in vivo, offers a unique opportunity to deliver a best-in-class therapeutic for cancers that have high unmet medical need. P7170 is currently in phase I clinical development.
Material and Methods
Cell lines, antibodies and compounds: All the cell lines (Huh7, 786-O, A549, A2780, PC3,   H460, HCT15, A431, SW480, HCT116, MDA MB 231, PANC1, HepG2, MCF7, MDA MB 468, AsPc-1), until and unless stated, were obtained from the American Type Culture Collection (ATCC) and cultured in ATCC recommended media at 37°C under 5% CO 2 . Patient derived cell lines were developed and maintained at Prof. Fiebig's lab, ONCOTEST, Germany. All cells were used within 20 passages from receipt and less than 6 months from authentication. All the primary antibodies were procured from Cell Signaling Technology (Danvers, MA), whereas secondary antibodies were procured from Santacruz Biotechnology (Dallas, TX Following incubation, cell viability was assayed using Propidium Iodide (PI) and percent inhibition was calculated using Graph Pad Prism software 6.0 (Graph Pad, San Diego, CA).
3D clonogenic assay:
The test tumor panel comprised of 13 different human tumor histology types, namely bladder cancer, colon, gastric, head and neck, liver, non-small cell lung adeno, squamous cell and large cell, mammary, ovary, pancreatic, prostate, renal cancer, malignant melanoma, pleuramesothelioma, and sarcoma. In addition, the compounds were tested against three plates onto the bottom layer. The test compounds were applied by continuous exposure (drug overlay) in 0.2 ml culture medium. The drug overlay was added 24 hrs after seeding the cells as 3-fold concentrated solution. Every plate included six untreated control wells and drug-treated groups in triplicate at 6 concentrations. Cultures were incubated at 37°C and 7.5% CO 2 in a humidified atmosphere for up to 20 days and monitored closely for colony growth using an inverted microscope. Within this period, in vitro tumor growth led to the formation of colonies with a diameter of > 50 µm. At the time of maximum colony formation (based on internal historical data, range 4 -21 days), counts were performed with an automatic image analysis 7 system (BIOREADER 5000-W, Biosys GmbH). Twenty four hours prior to evaluation, vital colonies were stained with a sterile aqueous solution of 2-(4-iodophenyl)-3-(4-nitrophenyl)-5-phenyltetrazolium chloride (1 mg/ml, 100 µl/well).
KINOMEscan™ Kinase assays: For most assays, kinase-tagged T7 phage strains were grown in parallel in 24-well blocks in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and infected with T7 phage from a frozen stock (multiplicity of infection = 0.4) and incubated with shaking at 32°C until lysis (90-150 minutes). The lysates were centrifuged (6,000 Rat aorta ring assay: Rat aortic ring assay was performed as described by Nicosia et al (22) with minor changes. Healthy rats were humanely euthanized by overdose of anesthesia followed by cervical dislocation. Animal's thoracic cavity was opened and using sterile fine forceps aorta was separated from vertebral column. A segment of aorta was excised between heart and thoracic aorta and kept in ice cold PBS supplemented with Penicillin-Streptomycin. Fine 1.0 mm aorta rings were prepared from aorta using scalpel blade and these rings were washed in ice cold Table S1B , C). Few kinases such as ABL1 (H396P), CLK1, HIPK2, LKB1, MEK2 and PIK3GC were also inhibited on P7170 treatment at 250 nM (Supplementary Table   S1C ). However, upon further evaluation of their IC 50 values, P7170 did not inhibit these set of kinases as efficiently as mTORC1/C2 or ALK-1 (Supplementary Table S1D ).
P7170 down regulates mTOR pathway.
To further evaluate the cellular PI3K/mTOR inhibitory activity of P7170, western blot analysis was carried out in A2780 cell line (Fig 1C) . (Fig.1C) . As demonstrated, the (IC 50 = 2.2 nM) PI3Kα biochemical activity translated into weak (IC 50 = >100 nM) inhibitory activity in ovarian cancer (A2780) cells (Fig.1C) . Some of the other kinase biochemical activities seem to be cell specific (manuscript in preparation) which is being explored intensively in our laboratories. P7170 activity was further evaluated in other cancer cell lines associated with activated PI3K/mTOR pathway (Fig. 1D) . Treatment with P7170 resulted in strong inhibition of mTORC1/C2 pathway in HCT116 (colon), 786-O (renal) and PC3 (prostate) cancer cell lines as shown in Figure 1D . 
P7170 exhibits anti-proliferative activity towards various cancer cell lines and patient-derived cancer cell lines. PI3K/mTOR pathway is known to play a central role in regulating fundamental cellular processes like proliferation, growth and survival (25) . Therefore, the impact of P7170 treatment was evaluated in a panel of cancer cell lines using a cell viability assay (Fig. 2A) .
P7170 treatment resulted in a dose dependent reduction in the number of viable cancer cells with IC 50 s ranging between 2-22 nM across a wide array of cancer cell types. No toxicity was observed in normal cells, hPBMCs, even on treatment with highest concentration (10 µM) of P7170, demonstrating a safe therapeutic window between cancer and normal cell types ( Fig. 2A ).
P7170 was then tested for its effect on the clonogenic growth of 99 patient derived cancer cell lines using a clonogenic assay. P7170 exhibited absolute mean IC 70 of 115 nM ( signal inhibition (27) . This considerable increase in sub-G1 population observed following P7170 treatment was dose-and time-dependent (Fig. 3B) . A 62% increase (over DMSO control) in sub-G1 (apoptotic) cell population upon treatment with P7170 led us to investigate potential outcome of this treatment on apoptotic pathways. However, P7170 when treated at 100 nM had no significant impact on PARP cleavage, a known apoptotic marker (Fig. 3C) . However, a dosedependent increase in PARP cleavage was observed at increasing concentration of P7170. mTOR inhibitors, in particular, are known to induce autophagy in various cancer cells (9) .Using acridine orange as an indicator of autophagy, the formation of cytoplasmic acidic vesicles was examined to evaluate the effect of P7170 on autophagosome formation in PC3 cells (Fig. 3D ).
P7170 induced a concentration-and time-dependent increase in acridine orange staining with maximum accumulation observed with 300nM in P7170 treated cells for 72 h (Fig. 3E) . A similar pattern of acridine staining was seen in A2780 and HCT116 cancer cell lines (Suppl. Fig.   S2 ). Detection of Microtubule-associated protein 1A/1B-light chain 3 (LC3) by immunoblotting has been reported as a reliable autophagosome marker for monitoring autophagy and autophagyinduced cell death (28) . P7170 demonstrated a dose-dependent increase in the expression of LC3-I and in particular, LC3-II (Fig. 3E) . Tracking the level of conversion of LC3-I to LC3-II is indicative of autophagic activity as the levels of LC3-II correlate with autophagosome formation.
Further, induction of autophagy by P7170 was comparable to the activities of known PI3K/mTOR inhibitor BEZ235, or mTOR inhibitor Everolimus (Fig. 3E) . Table S1C ). ALK1 has been implicated in vascular development and pathologic angiogenesis by numerous genetic and molecular mechanisms (19, 29) . Therefore, our subsequent efforts were focused on understanding the effect of P7170 on ALK1 activity and its implication on angiogenic processes. In comparison to BEZ 235 and Everolimus, P7170 strongly inhibited ALK1 kinase activity with IC 50 of 47 nM (Fig.1B) . Both BEZ 235 and Everolimus did not demonstrate any inhibition of ALK1 up to 2 µM, the highest concentration tested (Fig.1B) . Further, functional analyses in, in vivo and ex-vivo angiogenesis models (Fig.   4A&B , respectively) demonstrated P7170 to significantly impair angiogenic response toward vascular endothelial growth factor (VEGF). The anti-angiogenic activity of P7170 in vivo was assessed in a matrigel plug assay generated in nude mice and treated with 10 mpk of P7170 for 5 days. P7170 strongly inhibited angiogenesis as seen by diminished formation of blood vessels (Fig. 4A) . Also, VEGF at a concentration of 40 ng/mL significantly (p<0.05) induced microvasculature on rat aortic rings starting on day 2 (data not shown) and reached maximum on day 7 (Fig. 4B-C) . This VEGF induced aortic microvasculature was inhibited by P7170 in a dose dependent manner (Fig. 4B) . However, Everolimus and BEZ-235 had no significant effect on microvasculature formation (Fig. 4B) . The average microvasculature on control rings was 1327 µm 2 /µm and reduced to 42 µm 2 /µm upon P7170 treatment indicating 97% inhibition (Fig. 4C) .
Moreover, it may be noted that the plasma PK resulting from a dose of 10 mg/kg of P7170 is sufficient to inhibit ALK1 (Fig. 5D) . Although, PI3K/mTOR activity is reported to be important for VEGF signaling and angiogenesis, neither mTOR, and/or PI3K seems to be absolutely required for microvessel formation as Everolimus (a potent mTOR inhibitor) or BEZ235 (a PI3K/mTOR dual inhibitor) were ineffective in inhibiting microvessel formation in this ex vivo model.
In parallel, P7170 treatment resulted in complete loss of tube formation ability of HUVEC cells upon VEGF induction (Fig. 4D) at concentrations that were not cytotoxic and did not inhibit endothelial cell proliferation (data not shown). Also, in HUVECs, tube formation was compromised upon ALK1 knockdown by shRNA but not with scrambled shRNA (Fig. 4E ).
ALK1 knockdown was confirmed by immunocytochemistry (Fig. 4F) . No significant attenuation in tube formation is observed by P7170 in HUVEC cells that lack ALK1 suggesting ALK1 is the direct target of P7170.
P7170 induces significant tumor growth inhibition coupled with a strong pharmacodynamic effect on both pS6 and pAKT in a broad range of human tumor xenografts. In nude mice bearing PC3 (PTEN null) xenografts, oral administration of P7170 once a day resulted in a dosedependent tumor growth inhibition of 28%, 67% (p<0.002), 60% (p<0.001) and 76% (p<0.0001) with 3, 10, 12.5 and 15 mg/kg respectively (Fig. 5A) . P7170 also demonstrated substantial inhibition of tumor growth in renal (68%), ovarian (78%), colon (80%), and hepatocellular (53%) xenograft models when administered orally once daily at 5, 10, 15 and 20 mg/kg, respectively (Table 1 ). P7170 at dose of 15 mg/kg (76% TGI) was as efficacious as the mice treated with 25 mg/kg of BEZ235 (71%) in prostate xenograft model. No significant body weight loss was observed with increasing doses of P7170 (Fig. 5A, Inset) . (Fig. 5C ). This pharmacodynamic activity correlated well with the concentrations of the compound in plasma (Fig. 5D ).
Discussion
Phosphatidylinositol (PI3K)-AKT-mammalian target of rapamycin (mTOR) pathway has emerged as a prime strategic target of 'drugging the cancer kinome' that has led to the development of several novel targeted anti-cancer therapeutic agents (16, 17, 30, 31) . mTOR acts as a sensor protein that assimilates extracellular and intracellular events from many cancerdriving proteins such as PI3K, AKT, epidermal growth factor receptor (EGFR), HER2/neu and BCR-ABL (32) . It thus lies at the nexus of the regulatory network coordinating cellular proliferation, growth and survival (6) . Despite an increasing army of targeted agents that inhibit key components of PI3K-AKT-mTOR pathway (5, 6) there is still an unmet medical need to identify effective agents that would minimize toxicities and maximize clinical benefit, in order to improve and transform their care.
In the present work we describe P7170, a novel, orally bioavailable, potent, mTORC1/mTORC2 kinase inhibitor with distinctive inhibitory activity against Activin-like receptor kinase, ALK1. P7170 activity profile has been confirmed in a broad range of human 
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directly by phosphorylating ULK1 thus preventing ULK1-Atg13-FIP200 complex formation and indirectly by phosphorylating S6K and 4E-BP1 (36) . Reports on the involvement of mTORC2 protein rictor in regulating autophagy through a mechanism independent of mTORC1 have also started to emerge (35) further emphasizing the advantage of having a dual mTORC1 and mTORC2 inhibitor.
Recent literature has emphasized on the importance of angiogenesis in the progression of cancer development and use of anti-angiogenic agents as crucial therapeutic agents in cancer therapy (19, 37) . Interestingly, P7170, in addition to potently inhibiting mTORC1/C2 pathway, also effectively inhibits ALK1 activity (IC 50 47 nM). Activin receptor-like kinase 1 (ALK1) is a type I receptor of the transforming growth factor beta (TGF-β) receptor family, that is found on proliferating endothelial cells (38) . Hu-Lowe et al have demonstrated using ALK1 -/-mice and zebrafish harboring a loss-of-function mutation that ALK1 plays a fundamental role in vasculogenesis, particularly in vessel maturation and in the organization of neo-angiogenic vessels (19, 38) . In addition, overexpression of ALK1 has been observed in a wide variety of tumor blood vessels including lymphomas, prostate, skin, thyroid, kidney, ovarian, lung, pancreatic and liver cancers (39, 40) . Notably, recent development of two agents targeting (41, 42) . Based on these encouraging clinical activities, inhibition of ALK1 may turn out to be a promising novel antiangiogenic strategy to treat certain cancers. Our data from in vitro and ex vivo studies suggested that ALK1 is the direct target of P7170. Although, PI3K/mTOR dual activity is reported to be important for VEGF signaling and angiogenesis, mTOR doesn't seem to be absolutely required for microvessel formation as Everolimus (a potent mTOR inhibitor) or BEZ-235 (a PI3K/mTOR dual inhibitor) were ineffective in inhibiting microvessel formation in the ex vivo model as described in Figure 4B . This strongly suggests that ALK1 inhibitory activity by P7170 may be responsible for its effect on inhibition of microvessel formation.
Our results also demonstrate that P7170 was well tolerated and induced a dose dependent growth inhibition in a broad range of tumor xenografts. This anti-tumor activity was associated with a rapid and dose-dependent pharmacodynamic effect on both pS6 and pAKT providing evidence for target engagement by P7170 in vivo studies. Furthermore, the plasma PK resulting from a dose of 10 mg/kg P7170 is sufficient to achieve ALK1 inhibition.
In summary, having anti-angiogenesis (ALK1 Inhibition) activity in addition to potent activity against mTOR enzymes, P7170 may turn out to be of considerable therapeutic advantage in clinical setting. Therefore, P7170 is currently being evaluated in phase I studies in a variety of cancers. 
